There has been a rapid emergence of numerous targeted agents in the oncology community
in the last decade. This exciting paradigm shift in drug development lends promise for the …

Due to its high metabolic rate, skin represents one of the major target organs of
chemotherapy-associated toxicity. Reactions range from common, nonspecific …

The last decade has spawned an exciting new era of oncotherapy in dermatology, including
the development of targeted therapies for metastatic melanoma and basal cell carcinoma …

Dermatologic toxicities of targeted anticancer therapies. - Abstract - Europe PMC Sign in | Create
an account https://orcid.org Europe PMC Menu About Tools Developers Help Contact us Helpdesk …

Over the past 2 decades, rapid advancement in systemic anticancer therapeutics has led to
astounding improvement in survival rates of patients with cancer. However, this celebrated …

Chemotherapeutic agents give rise to numerous well described adverse effects that may
affect the skin, hair, mucous membranes, or nails. The mucocutaneous effects of …

Abstract International data from 2002 report 10.9 million new cases of cancer and 6.7 million
cancer deaths. Chemotherapy is an essential component in the multidisciplinary …

Background Dermatologic toxicities (DT) to targeted cancer therapy may present as
inflammatory dermatoses, keratoses, and as benign and malignant squamous proliferations …

Targeted drugs are increasingly being used for cancer management. They are designed to
block specific cancer cell processes, and are often better tolerated than conventional …

Targeted therapies and immunotherapies are associated with a wide range of dermatologic
adverse events (dAEs) resulting from common signaling pathways involved in malignant …